Navigation Links
Diabetes slows nerve recovery after heart transplant

Diabetes has a detrimental effect on a person's ability to recover from a heart transplant, notes a study in the September Journal of Nuclear Medicine.

"Using positron emission tomography (PET) and the transplanted heart as a very specific model to study the regenerative capacity of the heart's sympathetic nervous system, we determined that reinnervation--or the heart's ability to develop new nerves to replace damaged ones--is slower in diabetic patients," said Frank M. Bengel, a visiting associate professor of radiology and the director of cardiovascular nuclear medicine at Johns Hopkins Medicine's Russell H. Morgan Department of Radiology and Radiological Science in Baltimore, Md. "Our results confirm a detrimental effect of diabetes on the potential for recovery of sympathetic nerve fibers of the heart," added the co-author of "Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation."

"A better understanding of the importance of nervous system abnormalities and an imaging technique to precisely characterize nerve damage may be of value to guide future therapeutic efforts aimed at reducing cardiac risk with diabetes mellitus patients," explained Bengel, who was an associate professor at the Technical University of Munich, where the study was performed, prior to his move to Johns Hopkins. "Even if a transplant recipient is suffering from diabetes, there is still a chance for reinnervation--just at a slower speed," he added. "Unfortunately, there are no techniques developed yet that speed the nerve regeneration process," he said.

Currently, nuclear medicine techniques (such as PET) are the only imaging techniques that can measure the presence and function of the sympathetic nervous system of the heart, said Bengel. "There are invasive methods that allow for the measurement of neurotransmitters released to the blood, offering indirect conclusions about the presence, storage and releas e of neurotransmitters from neurons. These methods require complicated and laborious sampling of blood from coronary arteries and veins," he added.

Diabetes mellitus is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Such a deficiency results in increased concentrations of glucose (sugar) in the blood, which can damage many of the body's systems. Diabetes mellitus is a known major risk factor of heart disease, negatively affecting the heart's contraction and rhythm, said Bengel.

Future research will need to focus on how regeneration of sympathetic nerves can be facilitated and how changes of the sympathetic nerve integrity in the heart are interrelated with changes of prognosis and outcome of diseases like diabetes mellitus, said Bengel.

"Effect of Diabetes Mellitus on Sympathetic Neuronal Regeneration Studied in the Model of Transplant Reinnervation" appears in the September issue of the Journal of Nuclear Medicine, which is published by SNM. Other co-authors include Peter Ueberfuhr and Bruno Reichart, Ludwig-Maximilians University in Munich, Germany; and Dominik Schäfer, Stephan G. Nekolla and Markus Schwaiger, all with the Technical University of Munich, Germany.
'"/>

Source:Society of Nuclear Medicine


Related biology news :

1. FDA Approves New Drug to Treat Type I and Type II Diabetes
2. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
3. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
4. Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes
5. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
6. Diabetes hits 275 Australians each day as pandemic spreads
7. Diabetes research takes wing thanks to long-lived fruit fly
8. Cancer drug slows poxvirus in mice
9. Stress substantially slows human bodys ability to heal
10. Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice
11. Protein found that slows hepatitis C growth in liver cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology: